Strengths
GB Sciences has a robust R&D pipeline with five preclinical phase drug programs, indicating strong potential for future product development.
The company has a strong patent portfolio, including eight issued US patents and numerous global patents, which provides a competitive edge and protects its innovations.
The unique combination of AI technology and plant-based medicine allows GB Sciences to create rationally-designed therapies that enhance the efficacy of traditional treatments.
Collaboration with world-class researchers from nine international universities enhances credibility and fosters innovation in drug development.
The focus on specific diseases, such as Parkinson's and COVID-related hyperinflammation, positions GB Sciences to address significant unmet medical needs.
The PhAROS Drug Discovery Platform utilizes advanced AI to predict the efficacy of drug combinations, streamlining the drug development process.
The company's commitment to creating patented formulations of plant-inspired medicines aligns with the growing consumer interest in natural and plant-based therapies.
Positive media coverage, such as features on prominent business shows, increases visibility and can attract potential investors and partners.